Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
GlaxoSmithKline
Description:
Cancer of the uterine corpus, also called endometrial cancer (EC),
is the most common cancer of the female genital tract, with an
estimated 65,950 new cases diagnosed and 12,550 deaths annually in
the United States. The mortality rate has increased approximately 1%
each year from 2015 to 2019, an increase which may be related to a
higher rate of advanced-stage cancers, high-risk histologies, and
patients being diagnosed at an older age. There are significant
disparities between White and Black women regarding rates of
early-stage diagnosis (75% vs 62%) and 5-year relative survival (84%
vs 63%). When patients are diagnosed with distant-stage disease,
5-year relative survival rates plummet to 18% for all races. Early
identification of high-risk patients and personalized treatment
approaches for this complex, multifaceted disease are needed to
improve outcomes. Fortunately for patients with endometrial cancer,
new and emerging therapies, including immune based therapies such as
PD-1 Inhibitors, having recently been approved, giving managed care
professionals and clinicians more options for treating this patient
population. With so many new therapies entering the treatment
paradigm knowledge gaps have been created, making imperative that
managed care physician medical directors, oncologists, pharmacists,
payers, nurses and other healthcare professionals who manage EC
patient populations have a solid understanding of these options to
optimize both costs and patient outcomes in their therapeutic
application, for optimized clinical and economic outcomes.
Upon completion of this
activity, participants will be able to:
-
Examine the clinical and economic
burden of endometrial cancer (EC), including factors that
contribute to poor prognosis and increased costs
-
Recognize the role of biomarker
expression in the selection of most appropriate treatment
options for patients with endometrial cancer
-
Cite the rationales, therapeutic
roles, and key efficacy/safety evidence supporting the use of
immuno-oncology treatments for patients with recurrent or
advanced endometrial cancer
-
Analyze the guideline-recommended
role of PD-1 inhibitors in the management of endometrial cancer
-
Identify managed care directed
strategies to improve access to medication and overcome
treatment disparities in endometrial cancer
-
Implement cost of care and
utilization management strategies to optimize the use of PD-1
inhibitors in the treatment of endometrial cancer
Faculty:
Dario R. Roque, MD
Assistant Professor, Gynecologic Oncology
Gynecologic Oncology Fellowship Program Director
Department of Obstetrics & Gynecology
Feinberg School of Medicine at Northwestern University
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities. All faculty participating in this activity are required
to disclose to NAMCP/AAMCN any financial relationships with
ineligible companies. NAMCP/AAMCN in turn discloses all relevant
financial conflicts to the learners. NAMCP/AAMCN disclosure policy
adheres to The Standards for Integrity and Independence in
Accredited Continuing Education. All relevant conflicts of interest
have been mitigated prior to the commencement of the activity. See
below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Roque has served on the speaker's bureau for GlaxoSmithKline and
Myriad. He has served on an advisory board for GlaxoSmithKline and
Myriad. He has served as a consultant for Intuitive. All relevant
conflicts of interest have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships
with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an
ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an
ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship
with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions
for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring
material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
NAMCP and/or this website do not provide medical advice, diagnosis,
or treatment. NAMCP does not endorse or imply endorsement of the
content on any linked website. This website is to be used as an
informational resource. With any health-related concern, consult
with your physician or healthcare professional.
This activity is supported by an educational grant from
GlaxoSmithKline
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |